Aurinia Executes On Expanding It's Intellectual Property Estate [Seeking Alpha]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Seeking Alpha
Aurinia Executes On Expanding It's Intellectual Property Estate Summary Aurinia Pharmaceuticals is expected to receive an extension of their method of use patent to treat Lupus Nephritis with their novel calcinurine inhibitor, Voclosporin. The company previously expected to have market exclusivity in the US through 2028, and this new patent issuance would protect their dosing methods by another 9 years, until 2037. The removal of this intellectual property overhang makes Aurinia Pharmaceuticals a more attractive buyout target to a larger Pharmaceutical company treating renal diseases. Background on Aurinia Pharmaceuticals Aurinia Pharmaceuticals ( AUPH (Aurinia Pharmaceuticals Corporate Presentation, Phase II Aura Study) Voclosporin’s approval in Lupus Nephritis would mark the first approval for the disease, addressing a large, underserved patient population. Given the company’s phase II trial produced the highest complete remission rate at 48 weeks than any trial ever conducted for t
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference [Yahoo! Finance]Yahoo! Finance
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceBusiness Wire
- Pelthos Therapeutics Establishes Board of Directors [Yahoo! Finance]Yahoo! Finance
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024Business Wire
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceBusiness Wire
AUPH
Earnings
- 2/15/24 - Miss
AUPH
Sec Filings
- 3/20/24 - Form SC
- 3/7/24 - Form 4
- 3/7/24 - Form 4
- AUPH's page on the SEC website